0000000000530635

AUTHOR

Lodovico Frattola

showing 2 related works from this author

Bovine spongiform encephalopathy and Creutzfeldt-Jakob disease: facts and uncertainties underlying the causal link between animal and human diseases

2004

Following an outbreak of bovine spongiform encephalopathy (BSE) in dairy cows in the United Kingdom (UK), 153 definite and probable human cases of new variant Creutzfeldt-Jakob disease (nvCJD) have been reported, almost exclusively in the UK. Although exposure to the BSE agent is the most plausible interpretation for the occurrence of nvCJD, the causal link between the BSE prion and nvCJD is still debated. This review discusses the pros and cons of nvCJD as a separate nosographic entity, the scientific basis for a correlation between BSE and nvCJD, the validity of the current diagnostic criteria for CJD and nvCJD, the contribution of epidemiology to the detection of a causal relation betwee…

Pediatricsmedicine.medical_specialtyMeatEncephalopathy Bovine Spongiform Encephalopathy Bovine SpongiformBovine spongiform encephalopathyEncephalopathyDermatologyDiseaseCreutzfeldt-Jakob SyndromeAnimalsHumansMedicinebovine spongiform encephalopathybusiness.industryCausal relationsGeneral MedicineNew variantmedicine.diseaseVirologyCreutzfeldt-Jakob diseaseEncephalopathy Bovine SpongiformPsychiatry and Mental healthCattleCausal linkepidemiologyNeurology (clinical)business
researchProduct

Alpha-dihydroergocryptine in the treatment of de novo parkinsonian patients: results ofa multicentre, randomized, double-blind, placebo-controlled st…

2000

INTRODUCTION A multicentre, randomized, double-blind, placebo-controlled, parallel group study was carried out in 123 patients suffering from never treated (de novo) idiopathic Parkinson's disease (PD). The aim of the study was to confirm the efficiency and safety of alpha-dihydroergocryptine (alpha-DHEC) given as monotherapy in the symptomatic treatment of PD. The total score of the Unified Parkinson's Disease Rating Scale (UPDRS) was identified as the efficacy target variable. PATIENTS AND METHODS Sixty-two patients (32 males, 30 females, mean age +/- SD 64 +/- 10) were randomized to alpha-dihydroergocryptine and 61 (30 males, 31 females, mean age 63.8 +/- 9.1) to placebo. According to th…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentPlacebo-controlled studyGeneral MedicineInterim analysisPlacebomedicine.diseaseSurgeryCentral nervous system diseaseAnticonvulsantNeurologyInternal medicineStatistical significancemedicineNeurology (clinical)Analysis of variancebusinessActa Neurologica Scandinavica
researchProduct